FDA in focus
2024 review and 2025 outlookOur report, FDA in focus, highlights key guidance and developments from the Food and Drug Administration (FDA) DLA Piper’s FDA Regulatory practice followed in 2024, alongside insights and perspectives on what may come in 2025.
This deep dive focuses on the regulatory impacts of FDA’s activity on drugs and biologics, combination products, medical devices, digital health, food and dietary supplements, cosmetics, tobacco, cannabis, clinical trials, advertising and promotion of medical products, and enforcement and litigation.
We also discuss the 2025 outlook with respect to FDA’s ongoing priorities, as well as possible effects of the new US presidential administration.
Report: FDA in focus
In 2024, the FDA focused on enhancing its internal infrastructure and operations to address global supply chain complexities and product safety. Key priorities included medical product innovation, food safety, and enforcement activities.
- $7.2 million fiscal year budget for programmatic and operational changes
- Focus on clinical trial diversity and drug supply chain safety
- Emphasis on transparency and combatting misinformation
